APA (7th ed.) Citation

Baselga, J., Gomez, P., Greil, R., Braga, S., Climent, M., Wardley, A., . . . Awada, A. (2013). Randomized Phase 11 Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatis Triple-Negative Breast Cancer. American Society of Clinical Oncology.

Chicago Style (17th ed.) Citation

Baselga, J., et al. Randomized Phase 11 Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatis Triple-Negative Breast Cancer. American Society of Clinical Oncology, 2013.

MLA (9th ed.) Citation

Baselga, J., et al. Randomized Phase 11 Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatis Triple-Negative Breast Cancer. American Society of Clinical Oncology, 2013.